Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia

Summary

The purpose of this study is to evaluate a novel transplant strategy for the long-term benefit of patients with transfusion dependent high-risk thalassemia.

Timeline

Start

2022-03-22

Primary completion

2025-12-31

Completion

2026-12-31

Publications

• Raffa EH, Harris TM, Choed-Amphai C, Kirby-Allen M, Odame I, Ali M, Krueger J, Hermans KG, Tole S, Seelisch J, Klaassen RJ, Abbott L, Chopra YR, Wall DA, Chiang KY. Early Engraftment and Immune Kinetics Following Allogeneic Transplant Using a Novel Reduced-Toxicity Transplant Strategy in Children/Adolescents with High-Risk Transfusion-Dependent Thalassemia: Early Results of the ThalFAbS Trial. Transplant Cell Ther. 2025 Mar;31(3):180.e1-180.e12. doi: 10.1016/j.jtct.2024.12.016. Epub 2024 Dec 24.

Drugs

Indications